Document is current
Any future updates will be listed below
-
Authors
García-Vivar, Mª Luz
Prior-Español, Águeda
Fakhouri, Walid
Díaz-Cerezo, Silvia
Aguirregabiria, Itxaso
Moyano, Sebastián
Cobo, Amelia
Ogwu, Samuel
Trenor, Pilar
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 7 November 2024
Accepted: 23 June 2025
First Online: 7 July 2025
Declarations
:
: Mª Luz García Vivar declares payments or honoraria for consulting fees and/or lectures, presentations, writings or educational events and/or support attending meetings and/or participation on advisory board from: Janssen, UCB, Abbvie, Galápagos, Novartis, Amgen, Bristol, Lilly. Agueda Prior Español has no conflicts of interest to declare. Walid Fakhouri, Silvia Díaz-Cerezo, Itxaso Aguirregabiria, Sebastián Moyano, Amelia Cobo and Samuel Ogwu are employees and minor shareholders of Eli Lilly and Company. Pilar Trenor has no conflicts of interest to declare.
: This study was conducted in accordance with the Declaration of Helsinki and its amendments, the local laws and regulations and Good Clinical Practice guidelines. The study was approved by the ethics committee of the Hospital Universitario 12 de Octubre (Madrid, Spain). All patients provided written informed consent before their inclusion in the study.
